Robin M Joyce
Overview
Explore the profile of Robin M Joyce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avigan Z, Dias A, Dodge L, Arnason J, Joyce R, Liegel J, et al.
Transfusion
. 2024 May;
64(6):1068-1075.
PMID: 38693089
Background: CD34+ stem cells serve as the primary graft source for allogeneic transplants, with a minimum of 2-4 × 10 cells/kg needed for engraftment. There are conflicting data on outcomes...
2.
Merryman R, Rhoades J, Xiong K, Redd R, Antel K, An H, et al.
Hemasphere
. 2024 Apr;
8(4):e47.
PMID: 38566803
No abstract available.
3.
Merryman R, Redd R, Taranto E, Ahmed G, Jeter E, McHugh K, et al.
Blood Adv
. 2022 Nov;
7(17):4748-4759.
PMID: 36399518
Improved biomarkers are required to guide the optimal use of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual...
4.
Taranto E, Redd R, Jeter E, McHugh K, Crombie J, Fisher D, et al.
Leuk Lymphoma
. 2022 Aug;
63(12):2912-2917.
PMID: 35938581
Improved biomarkers are needed to guide patient selection for autologous stem cell transplantation (ASCT) and post-ASCT maintenance therapies in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the prognostic value of...
5.
Merryman R, Redd R, Jeter E, Wong J, McHugh K, Reynolds C, et al.
Transplant Cell Ther
. 2021 Oct;
28(1):32.e1-32.e10.
PMID: 34670169
Autologous stem cell transplantation (ASCT) is a standard of care for patients with chemosensitive, relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and diffuse large B cell lymphoma (DLBCL). Whereas the clinical...
6.
Rahimian M, Warner J, Salmi L, Rosenbloom S, Davis R, Joyce R
JAMIA Open
. 2021 Oct;
4(3):ooab051.
PMID: 34661067
Objective: The effects of shared clinical notes on patients, care partners, and clinicians ("open notes") were first studied as a demonstration project in 2010. Since then, multiple studies have shown...
7.
Merryman R, Redd R, Nishihori T, Chavez J, Nieto Y, Darrah J, et al.
Blood Adv
. 2021 Mar;
5(6):1648-1659.
PMID: 33710337
Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy,...
8.
Merryman R, Castagna L, Giordano L, Ho V, Corradini P, Guidetti A, et al.
Leukemia
. 2021 Mar;
35(9):2672-2683.
PMID: 33658659
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may...
9.
Frigault M, Armand P, Redd R, Jeter E, Merryman R, Coleman K, et al.
Blood Adv
. 2020 Jan;
4(1):122-126.
PMID: 31917843
Disease relapse remains the leading cause of failure after autologous stem cell transplantation (ASCT) for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase 2, multicenter,...
10.
Rahimian M, Warner J, Jain S, Davis R, Zerillo J, Joyce R
JCO Clin Cancer Inform
. 2019 Jun;
3:1-9.
PMID: 31184919
Purpose: OpenNotes is a national movement established in 2010 that gives patients access to their visit notes through online patient portals, and its goal is to improve transparency and communication....